Deliargyris Efthymios

SEC source: 0001104659-25-075791 · tm2522995-3_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2035-08-08

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-25-075791 · tm2522995-3_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 473,025

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F3 · balance_after: (continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and of which 30,500 remain unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iv) 197,525 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-25-005355 · tm254168-2_4seq1.xml · derivative · entry 4

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,233

Underlying: Common Stock · 16,233 shares

Expires 2025-04-10

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F8 · derivative.exercise_price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F8 · price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F9 · derivative.expiration_date: The Series B Right Warrants expire 90 calendar days following the Closing Date.

SEC source: 0001104659-25-005355 · tm254168-2_4seq1.xml · derivative · entry 3

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,233

Underlying: Common Stock · 16,233 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F7 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005355 · tm254168-2_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,233 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005355 · tm254168-2_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 403,025

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the "Common Stock") upon vesting: 55,000 RSUs granted on July 7, 2023 and of which 18,334 RSUs remain unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 148,691 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-107142 · tm2425809-2_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-10-04

F2 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F2 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR , subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-107142 · tm2425809-2_4seq1.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-10-04

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043795 · tm2411149-3_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043795 · tm2411149-3_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,433

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the "Common Stock") upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and

F5 · balance_after: (continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-042776 · tm2410664-4_4seq1.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,088

Underlying: Common Stock · 47,088 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-126431 · tm2332958-4_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,894

Underlying: Common Stock · 7,894 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126431 · tm2332958-4_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,433

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes: (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of Common Stock upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and

F5 · balance_after: (continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · derivative · entry 3

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-07-07

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,000

Underlying: Common Stock · 78,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080099 · tm2321021-1_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,648

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) (i) 120,000 RSUs granted on April 9, 2020 that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan");

F3 · balance_after: (continued from footnote 2) (b) the following RSUs: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (these RSUs cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date); (b) 55,000 RSUs granted on August 10, 2022 and unvested on the date hereof (these RSUs vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and (c) 55,000 RSUs granted on July 7, 2023 and reported on this Form 4; and

F4 · balance_after: (continued from footnote 3) (c) 46,981 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · derivative · entry 4

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 100,000 options will vest if the Company obtains one U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 50,000 options will vest if the Company obtains a second U.S. Food and Drug Administration approval for its product DrugSorb, (iii) 60,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iv) 60,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (v) 30,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · derivative · entry 3

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,000

Underlying: Common Stock · 74,000 shares

Expires 2032-08-10

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · nonDerivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,384

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes (a) (i) 120,000 RSUs granted on April 9, 2020 and (ii) 55,000 RSUs granted on August 10, 2022 and reported on this Form 4, in each case that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan";

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 13,334 RSUs granted on April 12, 2021 and unvested on the date hereof; (b) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof and (c) 52,000 RSUs granted on August 10, 2022 reported on this Form 4 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 23,050 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-22-090254 · tm2223355-5_4seq1.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,384

F7 · shares: These shares represent RSUs that will vest upon a "Change in Control" of the Company as defined in the Plan.

SEC source: 0001104659-21-050399 · tm2113016d5_4.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,250

Underlying: Common Stock · 63,250 shares

Expires 2031-04-12

F4 · derivative.exercise_date: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050399 · tm2113016d5_4.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,000

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) 120,000 RSUs granted on April 9, 2020 that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 40,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof; and (iii) 3,000 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-20-056881 · tm2018632-3_4.xml · derivative · entry 2

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,500

Underlying: Common Stock · 85,500 shares

Expires 2030-04-12

F1 · date: Dr. Deliargyris was appointed as Chief Medical Officer of CytoSorbents Corporation (the "Company"), effective May 1, 2020. This Form 4 is being filed to report certain transactions made in connection with that certain Employment Agreement, dated April 12, 2020, by and between Dr. Deliargyris and the Company (the "Employment Agreement").

F3 · derivative.exercise_date: Reflects the grant of a stock option to purchase 85,500 shares of the Company's Common Stock. The shares underlying the stock option will vest over four years from the date of the grant, with (i) 30,000 shares underlying such option vesting immediately on the date of grant and becoming exercisable on October 12, 2020, and (ii) the remaining 55,000 shares underlying such option vesting and becoming exercisable in three approximately equal installments on the first, second and third anniversary of the date of grant, in each case, subject to the Reporting Person's employment on the applicable vesting date.

SEC source: 0001104659-20-056881 · tm2018632-3_4.xml · nonDerivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,000

F1 · date: Dr. Deliargyris was appointed as Chief Medical Officer of CytoSorbents Corporation (the "Company"), effective May 1, 2020. This Form 4 is being filed to report certain transactions made in connection with that certain Employment Agreement, dated April 12, 2020, by and between Dr. Deliargyris and the Company (the "Employment Agreement").

F2 · shares: Reflects the grant of (i) 120,000 restricted stock units, which shall fully vest as of and only upon a Change of Control (as defined in the Employment Agreement) and subject to the Reporting Person's continued employment as of the consummation of the Change of Control and (ii) 20,000 restricted stock units, which vest upon the earlier of (a) a Change of Control and (b) April 12, 2024, in each case, subject to the Reporting Person's continued employment as of the applicable vesting date. The restricted stock units will automatically settle into shares of the Company's common stock, $0.001 par value per share (the "Common Stock") upon vesting.

F2 · balance_after: Reflects the grant of (i) 120,000 restricted stock units, which shall fully vest as of and only upon a Change of Control (as defined in the Employment Agreement) and subject to the Reporting Person's continued employment as of the consummation of the Change of Control and (ii) 20,000 restricted stock units, which vest upon the earlier of (a) a Change of Control and (b) April 12, 2024, in each case, subject to the Reporting Person's continued employment as of the applicable vesting date. The restricted stock units will automatically settle into shares of the Company's common stock, $0.001 par value per share (the "Common Stock") upon vesting.

SEC source: 0000921895-20-000902 · form411577002del_03242020.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-20

F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan.

F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date.

SEC source: 0000921895-19-000814 · form411577del_03182019.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-03-14

F1 · shares: Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan.

F2 · derivative.exercise_date: These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date.

SEC source: 0000921895-18-002522 · form411577002_08312018.xml · derivative · entry 1

Deliargyris Efthymios · CIK 0001751617 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2028-08-29

F1 · derivative.exercise_date: The stock options vest as follows: 23,333 options vest on August 29, 2019, 23,333 vest on August 29, 2020 and 23,334 options vest on August 29, 2021.